IRIS Accounts Production v24.1.0.578 02172900 Board of Directors 1.12.22 30.11.23 30.11.23 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh021729002022-11-30021729002023-11-30021729002022-12-012023-11-30021729002021-11-30021729002021-12-012022-11-30021729002022-11-3002172900ns15:EnglandWales2022-12-012023-11-3002172900ns14:PoundSterling2022-12-012023-11-3002172900ns10:Director12022-12-012023-11-3002172900ns10:PrivateLimitedCompanyLtd2022-12-012023-11-3002172900ns10:SmallEntities2022-12-012023-11-3002172900ns10:AuditExempt-NoAccountantsReport2022-12-012023-11-3002172900ns10:SmallCompaniesRegimeForDirectorsReport2022-12-012023-11-3002172900ns10:SmallCompaniesRegimeForAccounts2022-12-012023-11-3002172900ns10:FullAccounts2022-12-012023-11-300217290012022-12-012023-11-3002172900ns10:Director22022-12-012023-11-3002172900ns10:Director32022-12-012023-11-3002172900ns10:Director42022-12-012023-11-3002172900ns10:Director52022-12-012023-11-3002172900ns10:Director62022-12-012023-11-3002172900ns10:CompanySecretary12022-12-012023-11-3002172900ns10:RegisteredOffice2022-12-012023-11-3002172900ns5:CurrentFinancialInstruments2023-11-3002172900ns5:CurrentFinancialInstruments2022-11-3002172900ns5:ShareCapital2023-11-3002172900ns5:ShareCapital2022-11-3002172900ns5:CapitalRedemptionReserve2023-11-3002172900ns5:CapitalRedemptionReserve2022-11-3002172900ns5:RetainedEarningsAccumulatedLosses2023-11-3002172900ns5:RetainedEarningsAccumulatedLosses2022-11-3002172900ns5:NetGoodwill2022-12-012023-11-3002172900ns5:IntangibleAssetsOtherThanGoodwill2022-12-012023-11-3002172900ns5:LandBuildings2022-12-012023-11-3002172900ns5:PlantMachinery2022-12-012023-11-3002172900ns5:NetGoodwill2022-11-3002172900ns5:NetGoodwill2023-11-3002172900ns5:NetGoodwill2022-11-3002172900ns5:LandBuildings2022-11-3002172900ns5:LongLeaseholdAssetsns5:LandBuildings2022-11-3002172900ns5:PlantMachinery2022-11-3002172900ns5:LongLeaseholdAssetsns5:LandBuildings2022-12-012023-11-3002172900ns5:LandBuildings2023-11-3002172900ns5:LongLeaseholdAssetsns5:LandBuildings2023-11-3002172900ns5:PlantMachinery2023-11-3002172900ns5:LandBuildings2022-11-3002172900ns5:LongLeaseholdAssetsns5:LandBuildings2022-11-3002172900ns5:PlantMachinery2022-11-3002172900ns5:MotorVehicles2022-11-3002172900ns5:ComputerEquipment2022-11-3002172900ns5:MotorVehicles2022-12-012023-11-3002172900ns5:ComputerEquipment2022-12-012023-11-3002172900ns5:MotorVehicles2023-11-3002172900ns5:ComputerEquipment2023-11-3002172900ns5:MotorVehicles2022-11-3002172900ns5:ComputerEquipment2022-11-3002172900ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-11-3002172900ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-11-30
REGISTERED NUMBER: 02172900 (England and Wales)





UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 NOVEMBER 2023

FOR

TCS BIOSCIENCES LIMITED

TCS BIOSCIENCES LIMITED (REGISTERED NUMBER: 02172900)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


TCS BIOSCIENCES LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30 NOVEMBER 2023







DIRECTORS: Dr K Langston
Mrs L J Preston
Mr J E Preston
Mrs R V Toombs
Mrs E J Utley
Mr G A Williams





SECRETARY: Mrs R V Toombs





REGISTERED OFFICE: Botolph Farm
Botolph Claydon
Buckingham
Buckinghamshire
MK18 2LR





REGISTERED NUMBER: 02172900 (England and Wales)





ACCOUNTANTS: Martin and Company
Two Brewers House
50 North Street
Thame
Oxfordshire
OX9 3BH

TCS BIOSCIENCES LIMITED (REGISTERED NUMBER: 02172900)

BALANCE SHEET
30 NOVEMBER 2023

30.11.23 30.11.22
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 724,621 607,605
724,621 607,605

CURRENT ASSETS
Stocks 1,757,884 1,155,065
Debtors 6 1,614,243 2,380,923
Investments 7 966,228 841,229
Cash at bank and in hand 6,586,196 5,007,490
10,924,551 9,384,707
CREDITORS
Amounts falling due within one year 8 2,046,432 1,501,430
NET CURRENT ASSETS 8,878,119 7,883,277
TOTAL ASSETS LESS CURRENT
LIABILITIES

9,602,740

8,490,882

PROVISIONS FOR LIABILITIES 75,471 -
NET ASSETS 9,527,269 8,490,882

CAPITAL AND RESERVES
Called up share capital 850 850
Capital redemption reserve 150 150
Retained earnings 9,526,269 8,489,882
9,527,269 8,490,882

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 November 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 November 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

TCS BIOSCIENCES LIMITED (REGISTERED NUMBER: 02172900)

BALANCE SHEET - continued
30 NOVEMBER 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 August 2024 and were signed on its behalf by:





Mrs L J Preston - Director


TCS BIOSCIENCES LIMITED (REGISTERED NUMBER: 02172900)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023


1. STATUTORY INFORMATION

TCS Biosciences Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2008, is being amortised evenly over its estimated useful life of three years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Land and buildings - 2% on cost
Plant and machinery etc - 25% on cost

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


TCS BIOSCIENCES LIMITED (REGISTERED NUMBER: 02172900)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2023


2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 46 (2022 - 45 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 December 2022
and 30 November 2023 512,636
AMORTISATION
At 1 December 2022
and 30 November 2023 512,636
NET BOOK VALUE
At 30 November 2023 -
At 30 November 2022 -

TCS BIOSCIENCES LIMITED (REGISTERED NUMBER: 02172900)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2023


5. TANGIBLE FIXED ASSETS
Freehold Property Plant and
property improvements machinery
£    £    £   
COST
At 1 December 2022 615,611 11,439 740,773
Additions - - 60,097
Disposals - - (22,555 )
At 30 November 2023 615,611 11,439 778,315
DEPRECIATION
At 1 December 2022 178,098 11,439 576,988
Charge for year 14,775 - 59,967
Eliminated on disposal - - (22,555 )
At 30 November 2023 192,873 11,439 614,400
NET BOOK VALUE
At 30 November 2023 422,738 - 163,915
At 30 November 2022 437,513 - 163,785

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 December 2022 9,495 - 1,377,318
Additions - 164,824 224,921
Disposals - - (22,555 )
At 30 November 2023 9,495 164,824 1,579,684
DEPRECIATION
At 1 December 2022 3,188 - 769,713
Charge for year 2,374 30,789 107,905
Eliminated on disposal - - (22,555 )
At 30 November 2023 5,562 30,789 855,063
NET BOOK VALUE
At 30 November 2023 3,933 134,035 724,621
At 30 November 2022 6,307 - 607,605

TCS BIOSCIENCES LIMITED (REGISTERED NUMBER: 02172900)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 NOVEMBER 2023


6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.23 30.11.22
£    £   
Trade debtors 1,155,286 1,280,444
Amounts owed by group undertakings 380,885 458,545
Other debtors 78,072 641,934
1,614,243 2,380,923

7. CURRENT ASSET INVESTMENTS
30.11.23 30.11.22
£    £   
Listed investments 218,069 218,069
Unlisted investments 748,159 623,160
966,228 841,229

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.11.23 30.11.22
£    £   
Trade creditors 975,967 604,767
Amounts owed to group undertakings - 158,920
Taxation and social security 409,290 320,313
Other creditors 661,175 417,430
2,046,432 1,501,430